Is Retro Biosciences profitable in 2026?

No. Retro Biosciences is pre-revenue as of May 2026, with no confirmed paying commercial customers; it remains a clinical-stage biotech funded by a $180M seed from Sam Altman and a May 2026 financing round valuing it at $1.8B pre-money.

Could AI replace Retro Biosciences' scientists?

Not the clinical or regulatory work, but AI already does discovery work: OpenAI built GPT-4b micro with Retro, which redesigned Yamanaka factors into RetroSOX and RetroKLF, achieving a 50-fold increase in reprogramming marker expression, published by OpenAI on 2026-07-15.

Who is Retro Biosciences' biggest competitor?

Altos Labs is the most direct rival, having raised $3 billion in 2022 with backing from Jeff Bezos and Yuri Milner and Nobel laureate Shinya Yamanaka as advisor, far outspending Retro's $180M seed and $1.8B May 2026 valuation.

Who owns Retro Biosciences?

It is privately held, founded in 2021 by CEO Joe Betts-LaCroix, Sheng Ding, and Matt Buckley, seeded with $180M from Sam Altman in 2022, and as of May 2026 raised new capital led by 4P Capital at a reported $1.8B pre-money valuation.

Has Retro Biosciences had layoffs?

No layoffs are reported in available material as of July 2026; instead headcount estimates range from about 60 to 96 employees and the company is actively hiring for roles like Senior Instrument Engineer and Head of Clinical.

What is Retro Biosciences' lead drug candidate?

RTR242, an oral autophagy enhancer for Alzheimer's disease, entered Phase 1 trials in Australia with the first patient dosed by December 2025 and 8 participants enrolled; initial safety and efficacy data are expected around August 2026.

United States · United States

Retro Biosciences

Clinical-stage biotech chasing cellular reprogramming and autophagy drugs to slow aging, backed by Sam Altman.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: RTR242 Phase 1 safety and efficacy readout

The call

Retro's fate rests on one drug readout and one funding round closing, in a field where Altos Labs and Calico chase the same biology with deeper pockets.

Retro Biosciences is trying to develop drugs that slow or reverse aging by reprogramming cells. The company has raised a lot of money ($1.8 billion valuation) and started human testing in late 2025, which is fast for this kind of work. However, competitors like Altos Labs (backed by Jeff Bezos) and Calico (owned by Google's parent company) are also pursuing the same science with even more cash and resources, and no one has yet proven these drugs actually work in people. The company's fate hinges entirely on whether its first drug shows promise in human testing around August 2026 and whether it can continue raising money through a long, expensive development process that typically takes many years.

Why

AI pressure: Isomorphic Labs and other AI-native drug discovery labs. AI-first labs could design and test reprogramming or aging targets faster than Retro's wet-lab pipeline, though Retro also leans on AI internally. Could AI do the core job? Only partly.

Bigger players: Altos Labs and Calico. Both are pursuing the same cellular reprogramming and longevity biology with far more capital, but neither has a drug on the market yet. Could a giant copy it? Yes, easily.

What protects it. Retro moved from picking its Alzheimer's target to dosing a human in about 15 months, giving it real clinical data before most rivals.

What would change this call

RTR242 Phase 1 safety/efficacy data release, expected around August 2026. Would show whether the lead drug candidate is working or the thesis is failing.
Whether the May 2026 financing round fully closes with named institutional investors beyond 4P Capital. Would show if outside capital confidence beyond the initial lead investor is real.
Resolution of the $1.8B pre-money vs Preqin's $8B post-money valuation discrepancy. Would show the true scale and credibility of the company's latest valuation claim.

Key numbers

$1.8B pre-money valuation set in May 2026 raise (2026-05-22)
$180M seed round funded by Sam Altman, 2022 (2022)
First RTR242 patient dosed in Australia trial (2025-12)

Named risks

Zero revenue and outcome tied entirely to binary RTR242 Phase 1 readout expected August 2026. Severity: high
May 2026 financing round is only an initial close; full close and investor list beyond 4P Capital unconfirmed. Severity: high
Valuation conflict: STAT reports $1.8B pre-money while Preqin lists $8B post-money for same round, unresolved. Severity: medium
No approved longevity or reprogramming drug exists industry-wide; FDA does not recognize aging as an indication. Severity: medium
Better-capitalized rivals Altos Labs ($3B raised) and Alphabet-backed Calico pursue the identical cellular reprogramming thesis. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Altos Labs	losing to	Altos raised $3B in 2022 with Bezos/Milner backing versus Retro's $180M seed as of 2022
Calico	contesting	Alphabet-backed Calico pursues the same longevity thesis with deep incumbent resources, as of 2026-03-20
NewLimit and BioAge Labs	contesting	CB Insights lists Retro as a Leader alongside NewLimit, Immunis, Shift Bioscience in longevity tech, 2026-06-11

Questions people ask

Is Retro Biosciences profitable in 2026?: No. Retro Biosciences is pre-revenue as of May 2026, with no confirmed paying commercial customers; it remains a clinical-stage biotech funded by a $180M seed from Sam Altman and a May 2026 financing round valuing it at $1.8B pre-money.
Could AI replace Retro Biosciences' scientists?: Not the clinical or regulatory work, but AI already does discovery work: OpenAI built GPT-4b micro with Retro, which redesigned Yamanaka factors into RetroSOX and RetroKLF, achieving a 50-fold increase in reprogramming marker expression, published by OpenAI on 2026-07-15.
Who is Retro Biosciences' biggest competitor?: Altos Labs is the most direct rival, having raised $3 billion in 2022 with backing from Jeff Bezos and Yuri Milner and Nobel laureate Shinya Yamanaka as advisor, far outspending Retro's $180M seed and $1.8B May 2026 valuation.
Who owns Retro Biosciences?: It is privately held, founded in 2021 by CEO Joe Betts-LaCroix, Sheng Ding, and Matt Buckley, seeded with $180M from Sam Altman in 2022, and as of May 2026 raised new capital led by 4P Capital at a reported $1.8B pre-money valuation.
Has Retro Biosciences had layoffs?: No layoffs are reported in available material as of July 2026; instead headcount estimates range from about 60 to 96 employees and the company is actively hiring for roles like Senior Instrument Engineer and Head of Clinical.
What is Retro Biosciences' lead drug candidate?: RTR242, an oral autophagy enhancer for Alzheimer's disease, entered Phase 1 trials in Australia with the first patient dosed by December 2025 and 8 participants enrolled; initial safety and efficacy data are expected around August 2026.

Timeline

2026-07-15OpenAI publishes expanded GPT-4b micro results showing 50-fold reprogramming marker gain with Retro
2026-05-22Retro announces initial close of financing round led by 4P Capital at $1.8B pre-money valuation
2026-05-21Retro announces Murdoch Children's Research Institute partnership and Next Phase fundraise blog post
2025-12First patient dosed in RTR242 Phase 1 trial in Australia, 8 participants enrolled
2025-01OpenAI and Retro first announce GPT-4b micro protein-engineering model results
2024-05Retro signs $85M manufacturing agreement with Multiply Labs for individualized cell therapies
2022Retro emerges from stealth with $180M seed round funded by Sam Altman
2021Retro Biosciences founded by Joe Betts-LaCroix, Sheng Ding, and Matt Buckley

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.